Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

36.45p
   
  • Change Today:
    -0.30p
  • 52 Week High: 71.80
  • 52 Week Low: 34.50
  • Currency: UK Pounds
  • Shares Issued: 540.40m
  • Volume: 164,561
  • Market Cap: £196.98m
  • RiskGrade: 119

Alliance Pharma's revenues climb as 'star' products shine

By Duncan Ferris

Date: Monday 21 Jan 2019

LONDON (ShareCast) - (Sharecast News) - Alliance Pharma on Monday reported a jump in revenue after a strong performance from its 'star' products and newly acquired Nizoral brand.
For the year ended 31 December overall revenue increased by 22% to £124m compared to the year before, while revenues increased by 4% when not including new acquisitions and Alliance said it expects underlying profit before tax to fall in line with expectations.

Amongst the products driving the revenue increase was scar reduction gel Kelo-cote, which achieved a 68% rise in sales in to £22.5m thanks to booming demand in Asia and mainland Europe, Vamousse, which saw sales increase by 16% to £5.8m, and MacuShield, which achieved sales growth of 6% to £7m.

Meanwhile, pregnancy related nausea treatment Xonvea was launched in October 2018 and is on track with expectations, while anti-dandruff shampoo Nizoral, which was acquired from Johnson & Johnson in June, performed in line with expectations after bringing in £10.9m over the second half of the year.

On the downside, sales of local brands for the year were down 5% on the previous year at £77.8m, though free cash flow for the year was "slightly stronger than anticipated" at approximately £16.1m, down from £22.0m the year before.

Peter Butterfield, chief executive of Alliance Pharma, said: "We are very pleased to report continued strong momentum in our business, with sales in 2018 up 22% compared with the previous year. We look forward to delivering further growth in the year ahead and to employing the group's strong cashflow to further develop the business as the year progresses."

Analysts from Numis bumped up full-year revenue forecasts for Alliance by approximately 1% and estimated a reduction in net debt by the end of the current year, commending the company as "attractive" following a "continued strong performance".

Alliance Pharma's shares were up by 2.53% at 64.80p at 1217 GMT.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 36.45p
Change Today -0.30p
% Change -0.82 %
52 Week High 71.80
52 Week Low 34.50
Volume 164,561
Shares Issued 540.40m
Market Cap £196.98m
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
82.05% above the market average82.05% above the market average82.05% above the market average82.05% above the market average82.05% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
65.04% below the market average65.04% below the market average65.04% below the market average65.04% below the market average65.04% below the market average
15.79% above the sector average15.79% above the sector average15.79% above the sector average15.79% above the sector average15.79% above the sector average
Income
4.26% above the market average4.26% above the market average4.26% above the market average4.26% above the market average4.26% above the market average
25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average
Growth
88.65% below the market average88.65% below the market average88.65% below the market average88.65% below the market average88.65% below the market average
83.78% below the sector average83.78% below the sector average83.78% below the sector average83.78% below the sector average83.78% below the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 3
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Final Interim
Ex-Div 22-Jun-23 22-Dec-22
Paid 18-Jul-23 19-Jan-23
Amount 1.18p 0.59p

Trades for 19-Apr-2024

Time Volume / Share Price
12:36 2,136 @ 36.45p
12:26 1,000 @ 36.67p
12:24 700 @ 36.67p
11:25 2,710 @ 36.68p
10:55 1,100 @ 36.85p

Alliance Pharma Key Personnel

CEO Peter Butterfield
CFO Andrew Franklin
Chair Camillo Pane

Top of Page